Beneo oligofructose's potential in obesity

24 September 2006

Belgium's ORAFTI Active Food Ingredients, a subsidiary of the agro-food group Raffinerie Tirlemontoise/Tiense Suikerraffinaderji, says that the results of a recent study suggest that when Beneo oligofructose is incorporated into the diet it can limit feelings of hunger, thereby lowering energy intake.

The product belongs to a group of oligosaccharides called inulins, which are produced by some plants as an energy store.

Anne Franck, executive vice president of science and technology at ORAFTI, said that the induction of satiety that the compound brings about may provide a novel approach to the management of body weight and help to control obesity. A previously-completed study of the compound in an animal model found that it lowered both food intake and body weight, which provided the rationale for the initiation of assessment of the product as a treatment for human obesity.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight